Curenetics, Queen Mary University London (QMUL), Oracle Cancer Trust and South East Health Technologies Alliance (SEHTA) are working collaboratively to pioneer a transformative approach to oral cancer detection through the Novel AI-Enabled qMIDS Test. This groundbreaking project is poised to elevate precision cancer diagnostics by harnessing the power of artificial intelligence.
The research is funded by the National Institute for Health and Care Research (NIHR), the research partner of the NHS, public health and social care.
The Novel AI-Enhanced qMIDS Test, an innovative fusion of state-of-the-art technologies, presents a revolutionary solution to the challenge of oral cancer diagnosis. By integrating AI with the quantitative Malignancy Index Diagnostic System (qMIDS), rapid and accurate oral cancer detection is now possible even in the presence of seemingly inconspicuous mouth lesions. The test employs reverse transcription quantitative PCR to analyse the expression levels of 16 genes (mRNA) within a minimally invasive 1mm tissue biopsy. These gene expression profiles are then translated into a clinically meaningful quantitative malignancy index through an AI-powered algorithm, enabling precise stratification of cancer risk.
This cutting-edge research initiative represents a collaboration between the fields of oral cancer medicine, cancer biology and artificial intelligence. The research team is led by Dr Sola Adeleke, Dr Muy-Teck Teh, Dr Barbara Carey, Tamara Kahn, and experts from SEHTA. Together they bring a wealth of expertise and a shared dedication to pushing the boundaries of cancer diagnostics.
Dr Sola Adeleke, Founder of Curenetics, expressed the immense significance of this partnership: "Our collaboration with QMUL and Oracle Cancer Trust, under the auspices of NIHR, marks a giant stride in validating the Novel AI-Enhanced qMIDS Test. This research holds the potential to revolutionise the way we approach cancer diagnosis, offering an unprecedented level of accuracy and speed that has the potential to redefine patient care."
Curenetics is a med-tech company working to leverage AI technology to redefine the landscape of disease detection and treatment response prediction. Learn more by visiting the website at www.curenetics.io
